Jump to navigation

Free Newsletter Modern Trader Follow

Main menu

  • Futures
    • Modern Trader Magazine
    • Commodities
    • Futures Mag Archives
    • ETFs
    • Financials
    • Forex
    • Managed Funds
    • Market Analysis
    • News
    • Options
    • Regulation
    • Technology
    • Trading Strategies
    • Education
    • Futures Op-Ed
  • Favorites
    • Alpha Pages Most Popular
    • Futures Magazine
    • Modern Trader Magazine
    • Most Popular
    • Slideshows & Lists
    • Special Topics
      • Alpha Hunters
      • Bad Boys
      • FINtech
      • High-Frequency Trading
      • Trader's Life
      • Trading Strategies
      • FUTURES MAG's 500th ISSUE
      • We asked traders
  • Traders
    • Market Data
    • Hot Charts
    • Interactive Charts
    • Trading Calendar
  • FINalternatives
  • Hard Assets
    • Home
    • Base Metals
    • Precious Metals
    • Rare Earth Metals
    • Commodities
    • Mining Investments
    • Slideshows
  • Modern Trader
    • Subscribe
    • Past Issues
  • All +
    • Follow Us +
      • FuturesMag
      • Newsletters
      • Facebook
      • Google+
      • Linkedin
      • Twitter
      • RSS Feeds
    • About Us +
      • About
      • Advertise
      • Contact
      • Contribute
      • Privacy Policy
  • !
Follow Futures          
       
more >>

We Asked Traders

Top things I learned about life while day trading millions

Sponsored Content

Trading

Equities.com launches unlimited trading via Tradier Brokerage, Transforming into a news & fintech portal

Featured Topics

more Commodities>>

Commodities

A Saudi-Iran oil war could break up OPEC
Advertisement
more Volatility>>

Volatility

Implied vs. Realized Volatility & the VIX
more Financials>>

Financials

Making drones work for you
more Financials>>

Financials

Perspective: S&P 500 short side off highs

Pfizer revenue misses estimates as top drugs disappoint

By Reuters

May 2, 2017 • Reprints

Pfizer Inc (PFE.N), the largest U.S. drugmaker, reported quarterly revenue that missed estimates as sales of its key drugs fell short of expectations.

Sales of breast cancer drug Ibrance, which is expected to face competition from rival Novartis AG's (NOVN.S) Kisqali, rose more than 58 percent to $679 million, but missed the consensus estimate of $682 million, according to Barclays.

"Key franchises came in well below expectations, raising concerns about Pfizer's ability go grow in the absence of M&A," Goldman Sachs analysts said.

Sales of the company's arthritis drug Xeljanz were particularly weak, the analysts said, adding that cancer drug Xtandi and Prevnar vaccine also came in lower than expectations.

Pfizer said three fewer selling days in the quarter, compared with the year-ago quarter, reduced sales by about $300 million, surprising some Wall Street analysts.

"Pfizer calls out a deficit of selling-days ... Given that multiple major products fell just to the short side of our estimates, we are inclined to agree," Bernstein analyst Richard Wagner wrote in a client note.

The company also lost marketing exclusivity for its depression drug Pristiq in the United States during the quarter.

Overall, sales of Pfizer's array of patent-protected drugs jumped about 12% in the quarter to $7.42 billion, while sales of its generics and biosimilars fell 10% to $5.36 billion.

Revenue fell 1.7% to $12.78 billion, missing the average estimate of $13.09 billion.

Pfizer, which closed its $14 billion acquisition of Medivation Inc in September, said net profit rose to $3.12 billion, or 51 cents per share, in the first quarter, from $3.04 billion, or 49 cents per share, a year earlier.

Total expenses fell 6 percent to $7.49 billion in the quarter.

Excluding items, the company earned 69 cents per share, beating the average analyst estimate of 67 cents, according to Thomson Reuters I/B/E/S.

Pfizer reaffirmed its 2017 adjusted earnings forecast of $2.50-$2.60 per share on revenue of $52 billion-$54 billion.

The company's shares were down 0.8 percent at $33.50 in premarket trading.

About the Author

Related Articles
Making drones work for you
CTAs vs Central Banks: The QE Effect
Pardo: System designer has another upgrade
Keys in designing quant strategies
NZD/JPY collapses as NZ Business Confidence hits lowest level in decade
Previous
Fintech Exchange 3.0
Next
Morning Mash
Related Terms
Pfizer 16

Free Newsletter Modern Trader Follow

Main menu

  • Futures
    • Modern Trader Magazine
    • Commodities
    • Futures Mag Archives
    • ETFs
    • Financials
    • Forex
    • Managed Funds
    • Market Analysis
    • News
    • Options
    • Regulation
    • Technology
    • Trading Strategies
    • Education
    • Futures Op-Ed
  • Favorites
    • Alpha Pages Most Popular
    • Futures Magazine
    • Modern Trader Magazine
    • Most Popular
    • Slideshows & Lists
    • Special Topics
      • Alpha Hunters
      • Bad Boys
      • FINtech
      • High-Frequency Trading
      • Trader's Life
      • Trading Strategies
      • FUTURES MAG's 500th ISSUE
      • We asked traders
  • Traders
    • Market Data
    • Hot Charts
    • Interactive Charts
    • Trading Calendar
  • FINalternatives
  • Hard Assets
    • Home
    • Base Metals
    • Precious Metals
    • Rare Earth Metals
    • Commodities
    • Mining Investments
    • Slideshows
  • Modern Trader
    • Subscribe
    • Past Issues
  • All +
    • Follow Us +
      • FuturesMag
      • Newsletters
      • Facebook
      • Google+
      • Linkedin
      • Twitter
      • RSS Feeds
    • About Us +
      • About
      • Advertise
      • Contact
      • Contribute
      • Privacy Policy
  • !
images